Bhavin Dave, MD
Gastroenterology · Dover, DENPI 1144202300
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), food and beverage and gifts — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $7,237 and has fallen 90.5% since, to $685 in 2025. Among gastroenterology clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $58.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Gilead$800
- Johnson & Johnson$374
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$347
- Boston Scientific$309
- Madrigal Pharmaceuticals$309
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$6,00054%
- Food & beverage$4,65542%
- Education$1591%
- Gifts$2502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 53 | $7,349 |
| Gilead | 24 | $800 |
| Johnson & Johnson | 16 | $374 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $347 |
| Boston Scientific | 16 | $309 |
| Madrigal Pharmaceuticals | 4 | $309 |
| Braintree Laboratories, Inc. | 7 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $223 |
| Lilly USA, LLC | 2 | $163 |
| Olympus America Inc. | 8 | $143 |
| Phathom Pharmaceuticals, Inc. | 2 | $134 |
| Ardelyx, Inc. | 1 | $120 |
| Bristol Myers Squibb | 1 | $101 |
| Intercept Pharmaceuticals, Inc. | 5 | $98 |
| Haemonetics Corporation | 1 | $98 |
| Redhill Biopharma Inc. | 5 | $75 |
| Ironwood Pharmaceuticals, Inc | 3 | $47 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,065 in reported general payments places this provider in the 90th percentile of 50 gastroenterology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 79 | $87,184 |
| XifaxanRifaximin | 11 | $47,143 |
| CreonLipase/Protease/Amylase | 13 | $26,511 |
| TrulancePlecanatide | 28 | $18,264 |
| Mesalamine | 14 | $14,179 |
| MovantikNaloxegol Oxalate | 17 | $9,123 |
| Ursodiol | 11 | $5,154 |
| Esomeprazole Magnesium | 99 | $3,239 |
| Budesonide DrBudesonide | 23 | $2,638 |
| Omeprazole | 117 | $2,568 |
| Pantoprazole Sodium | 144 | $1,984 |
| Mesalamine ErMesalamine | 16 | $1,970 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 36 | $1,893 |
| Colestipol Hcl | 18 | $1,326 |
| Lactulose | 14 | $679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $7,349 | $113,69492 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $347 | $65,40739 claims |
| Redhill Biopharma Inc.Movantik | $75 | $9,12317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 gastroenterology providers in Delaware.
Other gastroenterology in Dover
- Abhishek AgnihotriDover$28K
- Michal BartelDover$6K
- Temitayo GboluajeDover$2K
- Mithil Gowda SureshDover$2K
- Muhammad HanafiDover$619
- Michael BrooksNewark$48K
- Richard CarusoLewes$13K
- Michael BassWilmington$11K
- Christopher RuffiniNeward$11K
- Jorge UribeNewark$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.